Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth…

By A. Buzdar, N. Ibrahim, D. Francis, D. Booser, E. Thomas, R. Theriault, L. Pusztai, M. Green, B. Arun, S. Giordano and 10 more. Journal of Clinical Oncology, 2005

1,168 citations recorded by the source corpus.

Subfields: Cancer Research, Cardiology and Cardiovascular Medicine, Oncology

View Paper: https://www.semanticscholar.org/paper/a9529bcbcbd0f83dc55ea87f1b82079d4fef63f8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Goldhirsch
2. A. Coates
3. Swati Biswas
4. R. Gelber
5. B. Thürlimann
6. Diane D Liu
7. H. Senn
8. J. J. Lee

Citations in the corpus

• Bayesian Clinical Trials at the University of Texas M. D. Anderson Cancer Center (2009, background): “Example 1: Neoadjuvant therapy for human epidermal growth factor receptor 2 (HER2/neu)positive operable breast cancer [19].”
• Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. (2005, background): “Promising results in the neoadjuvant setting [46] require confirmation.”